CN115400175A - Traditional Chinese medicine composition for treating chronic renal failure - Google Patents

Traditional Chinese medicine composition for treating chronic renal failure Download PDF

Info

Publication number
CN115400175A
CN115400175A CN202211086171.1A CN202211086171A CN115400175A CN 115400175 A CN115400175 A CN 115400175A CN 202211086171 A CN202211086171 A CN 202211086171A CN 115400175 A CN115400175 A CN 115400175A
Authority
CN
China
Prior art keywords
parts
powder
traditional chinese
chinese medicine
plaster
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202211086171.1A
Other languages
Chinese (zh)
Other versions
CN115400175B (en
Inventor
李益谦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to CN202211086171.1A priority Critical patent/CN115400175B/en
Publication of CN115400175A publication Critical patent/CN115400175A/en
Application granted granted Critical
Publication of CN115400175B publication Critical patent/CN115400175B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/63—Arthropods
    • A61K35/64—Insects, e.g. bees, wasps or fleas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/06—Fungi, e.g. yeasts
    • A61K36/062—Ascomycota
    • A61K36/066—Clavicipitaceae
    • A61K36/068—Cordyceps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/11—Pteridophyta or Filicophyta (ferns)
    • A61K36/12—Filicopsida or Pteridopsida
    • A61K36/126—Drynaria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/232—Angelica
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/236—Ligusticum (licorice-root)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/286—Carthamus (distaff thistle)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/324—Boswellia, e.g. frankincense
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/32—Burseraceae (Frankincense family)
    • A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
    • A61K36/708—Rheum (rhubarb)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • A61K36/716—Clematis (leather flower)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/74—Rubiaceae (Madder family)
    • A61K36/744—Gardenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/756—Phellodendron, e.g. corktree
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Abstract

The invention relates to a traditional Chinese medicine composition for treating chronic renal failure, which comprises orally taken uremia toxin detoxifying powder and externally used Shenshu black plaster, wherein the uremia toxin detoxifying powder comprises the following medicinal materials in parts by weight: 15 parts of lychee seed, 5 parts of cordyceps militaris or cordyceps sinensis, wherein the Shenshu black paste comprises traditional Chinese medicine powder consisting of the following medicinal materials in parts by weight: 720 parts of safflower, 450 parts of pseudo-ginseng, 480 parts of rhubarb, 720 parts of frankincense, 720 parts of myrrh, 600 parts of sappan wood, 600 parts of cape jasmine, 450 parts of wood louse, 480 parts of native copper, 300 parts of ligusticum wallichii, 360 parts of angelica, 360 parts of radix clematidis, 480 parts of rhizoma drynariae and 480 parts of golden cypress.

Description

Traditional Chinese medicine composition for treating chronic renal failure
Technical Field
The invention relates to the technical field of traditional Chinese medicines, and particularly belongs to a traditional Chinese medicine composition for treating chronic renal failure.
Background
According to statistics, the disease condition of the diabetic patients is 10-20 years. Clinical renal lesions occur in 50% of all ages. About 5% -15% of diabetics die from renal failure. Diabetic renal failure, kidney replacement is not of great significance. If life extension is desired, the only clinical solution is "renal dialysis", which is known by the general public as "kidney washing". At present, almost all domestic public hospitals are provided with 'dialysis departments', and a plurality of private clinics are also provided with 'dialysis departments'. The number of patients is not too small, the real number is not published, and the eye contact and the heart are believed to be surprised.
According to Chen national great initiative edition "modern emergency internal medicine" (page 358), show: dialysis (renal washing) indications for chronic renal failure:
(1) BUN (urea nitrogen) is more than or equal to 28.6mmol/L, (2) serum creatinine is more than or equal to 530.4umol/L, (3) Ccr is close to 10ml/min, and (4) serum potassium is more than or equal to 6.5mmol/L. (5) There is significant retention of water and sodium or complications of the nervous system.
The basic diagnostic and treatment standard of common diseases in Guangdong province, which divides the clinical manifestations of diabetic nephropathy into 5 stages:
stage I: in the initial stage of diabetic nephropathy, only the clinical manifestations of diabetes are present.
And stage II: in microalbuminuria, the urine protein excretion rate after activity is 20-200ug/min (or 30-300mg/24 h).
Stage III: early diabetic nephropathy, urinary protein excretion rate of more than 200ug/min (or 300mg/24 hr), urinary protein excretion rate of more than 0.5g/24 hr, and mild hypertension.
And IV, period: clinical diabetic nephropathy has obvious proteinuria and hematuria, which is manifested as nephrotic syndrome.
And stage V: end stage renal failure.
After diabetes enters the renal function impairment stage, the disease of some people progresses rapidly. Kidney damage was found shortly before and uremia developed in less than a few months. At this time, no matter the western medicine, the treatment effect is not ideal, and only the kidney can be replaced or dialyzed.
The traditional Chinese medicine considers that uremia is a syndrome group of severe metabolic disorders in various aspects of a human body caused by abnormal excretion and regulation functions of kidneys due to kidney function weakness. The onset of the disease is due to the chronic or mishandling of kidney disease, which leads to the progressive decline of kidney function, deficiency of spleen qi, and no excretion of damp-toxin. The adverse flow of qi is dry in the upper part, and coma in the head and eyes can be seen. Tarnish, frequent vomiting, dysphoria and coma, scanty stool and urine, high blood pressure, wiry and thready or thready and rapid pulse, etc. The deficient healthy qi and excessive pathogenic factors may cause the separation of yin and yang, and if there is no effective measure, the death may occur immediately.
According to clinical observation, after the kidney function is damaged, the kidney function is basically progressive, only the progression speed is fast and slow, and the self-healing is hardly possible.
A drug or method is developed that prevents or delays progression to end-stage renal failure prior to uremia. Has great clinical significance.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provide the traditional Chinese medicine composition for treating chronic renal failure, and the traditional Chinese medicine method for tonifying spleen and kidney, promoting blood circulation and removing blood stasis is adopted, so that the renal failure at the final stage can be effectively prevented or delayed.
In order to achieve the purpose, the technical scheme provided by the invention is as follows: the provided traditional Chinese medicine composition for treating chronic renal failure comprises uremia toxin detoxification powder which is taken orally and a Shenshu black plaster which is externally used for strengthening the spleen, tonifying the kidney and improving the blood flow of the kidney, wherein the uremia toxin detoxification powder comprises the following medicinal materials in parts by weight: 15 parts of lychee seed, 5 parts of cordyceps militaris or cordyceps sinensis, wherein the Shenshu black paste comprises traditional Chinese medicine powder consisting of the following medicinal materials in parts by weight: 720 parts of safflower, 450 parts of pseudo-ginseng, 480 parts of rhubarb, 720 parts of frankincense, 720 parts of myrrh, 600 parts of sappan wood, 600 parts of twig, 450 parts of wood louse, 480 parts of native copper, 300 parts of ligusticum wallichii, 360 parts of angelica, 360 parts of radix clematidis, 480 parts of rhizoma drynariae and 480 parts of golden cypress.
Preferably, the uremia toxin-removing powder is orally taken after being boiled with pig waist and rice washing water and then deslagging.
Preferably, the Shenshu black plaster consists of a hot melt adhesive matrix, traditional Chinese medicine powder and plaster auxiliary material powder.
Preferably, the Shenshu black plaster is prepared by mixing hot melt adhesive matrix, traditional Chinese medicine powder and plaster auxiliary material powder according to the weight ratio of 1000:300 to 350.
Preferably, the plaster auxiliary material powder is composed of one or more of penetrant azone powder, far infrared ceramic powder, analgesic powder, antiallergic powder and heating agent.
Preferably, the plaster auxiliary material powder comprises penetrant azone powder, far infrared ceramic powder, analgesic powder, antiallergic powder and heating agent according to the ratio of 20 to 40:30 to 50:10 to 30 parts by weight, and.
Preferably, the heating agent is a capsaicin heating agent or an oil vanilla heating agent.
Preferably, the Shenshu black plaster is prepared by heating and melting 1000g of hot melt adhesive matrix, melting at 120-140 deg.C, not more than 150 deg.C, stirring while melting, converting into fluidized state after completely melting, adding Chinese medicinal powder and plaster adjuvant powder, stirring, covering with a barrier film, and flattening.
The invention has the advantages that: the traditional Chinese medicine composition for treating chronic renal failure can effectively prevent or delay uremia by adopting a traditional Chinese medicine method of tonifying spleen and kidney, promoting blood circulation and removing blood stasis.
Oral uremia detoxifcation powder
According to the theory of traditional Chinese medicine, kidneys are the congenital foundation and the residence of water and fire. The balance between yin and yang of the kidney, and the transformation of yang into water and fluid distribution, the body is harmonized. If kidney yang deficiency fails to transform qi into water, water will overflow and edema will occur around the body; if it attacks the lung, it will cause palpitation and dyspnea; the waist is house of kidney, and the deficiency of kidney yang causes lumbago; the decline of the fire from the gate of life will make the limbs warm. Zhenwu decoction is a prescription for treating shaoyin cold transformation syndrome in Shang Zhang Zhong Jing Shang Han Lun of doctor, has the functions of warming yang, transforming qi and promoting diuresis, and is a representative prescription for treating edema due to kidney yang deficiency in later generations. In the recipe, fu Zi is the essential herb for warming kidney and restoring yang from collapse. And the amount of the medicine is more than three money.
The key to the pathogenesis of chronic nephritis is spleen and kidney deficiency. Spleen qi deficiency failing to transport and transform. On the one hand, insufficient qi and blood are produced, qi deficiency makes blood circulation impossible, blood circulation slow, blood stasis occurs after a long time, and internal cold is produced when the qi deficiency further develops into yang deficiency. Blood stasis can also be formed due to cold stagnation. On the other hand, spleen deficiency can cause water-dampness retention. Qi deficiency of the kidney may lead to dysfunction of the qi transformation of the kidney. That is, the kidney fails to function properly to expel its essence and coarse essence (under the condition of the Chinese yam in Shen Long Ben Cao Jing Shu), so that the toxic substances such as coarse essence stay in the kidney meridian. Can block the renal collaterals. Damp-stasis and other heat-induced toxicity. Therefore, the pathogenesis of chronic nephritis is spleen and kidney qi deficiency and internal retention of damp-heat and blood stasis toxin. Therefore, it is treated with BUYANGHUANWU decoction (revised formula of Yi Lin). All doctors in the past can achieve satisfactory effect. The amount of the qi-tonifying medicine astragalus used in the formula is 1-4 per dose.
It can be seen that Fu Zi and Huang Qi are important drugs for the treatment of chronic nephritis in physicians of all generations.
Radix Aconiti lateralis is the lateral root of Aconitum carmichaeli Debx of Ranunculaceae, and has the symptoms of pungent taste, strong heat and toxicity. The main toxic component is aconitine. It is suitable for being cooked clinically. The decoction containing radix Aconiti lateralis should be decocted for a minimum time of more than one hour. It is considered to have the essential herbs for restoring yang, rescuing collapse, dispelling cold and alleviating pain.
The semen litchi is dry mature seed of fructus litchi of Sapindaceae. Belongs to pungent and warm medicinal materials, enters kidney and liver meridians and tastes cool and bitter. It has the actions of activating and purging with pungent and bitter taste, warming property and dispelling cold, soothing liver and regulating qi, moving qi and dissipating nodulation, dispersing cold and alleviating pain. Sometimes it is as effective as the vertical pole. But is characterized by almost no toxicity.
It is contemplated that chronic renal function impairment may be a longer course of treatment. The lychee seeds with small toxicity and similar functions are used for replacing the monkshood with larger toxicity, and the observation of the curative effect is the same and ideal.
Astragalus membranaceus, as documented, (1) has a strengthening effect, so-called "invigorating qi", and may be related to its sex hormone-like action and central nervous system stimulating action. (2) And (3) diuresis: however, the effective dosage range is small, and the urine volume is reduced when the dosage is too small or too large. (3) Anti-nephritis: has certain anti-inflammatory effect on experimental nephritis, and is especially helpful for removing proteinuria. (4) And (3) reducing the pressure: animal experiments prove that the traditional Chinese medicine composition has the function of reducing blood pressure and may be related to blood vessel dilation.
Cordyceps militaris is neutral in nature and sweet in taste, is beneficial to lung and kidney, can stop bleeding and reduce phlegm, and can treat weakness of old people, anemia and weakness and the like. Zhao Zhi Ming in Ben Cao gang mu Shi Yi (supplement of materia Medica): cordyceps militaris can treat all kinds of deficiency and all kinds of loss. The clinical medical effect of the cordyceps militaris is not inferior to that of the cordyceps militaris (the primary formula is the cordyceps militaris, and the cordyceps militaris is used instead because the medicine is too expensive), and the cordyceps militaris contains abundant cordycepic acid, cordycepin, ergosterol and the like, and has the effects of expanding trachea, calming, resisting various bacteria and reducing blood pressure. Cordycepin can also be used for treating cerebral thrombosis, cerebral embolism, vasospasm, cerebral hemorrhage, etc., and promoting metabolism and diuresis. Cordyceps polysaccharide can improve detoxicating ability of liver, and has liver protecting effect.
Replacing radix astragali with Cordyceps militaris with better function.
The lychee seed and the cordyceps militaris are adopted as main medicines of the uremia antidote, and the practice proves that the effect is obvious.
It should be noted here that the detoxification powder can not be taken orally like the decoction of general traditional Chinese medicine, but the patients with pencils have tried to take orally with water decoction, and the result is basically without curative effect, and the detoxification powder is only effective after being added with rice washing water and pig waist to be steamed together. The reason has not been elucidated. Whether the traditional Chinese medicine composition is related to certain vitamins in rice washing water and certain active substances in pig loins or not, whether the principle of 'tonifying the form by the form' in the traditional Chinese medicine is needed to be discussed later, and clinical observation shows that the traditional Chinese medicine composition has obvious reduction effects on urea nitrogen and creatinine after three times of administration.
Shenshu black plaster:
in chronic renal failure (CFR), modern researches show that in the chronic renal failure, blood viscosity is increased and easy to solidify, and in addition, blood fat is high, so that blood flow is slowed down, and the secondary glomerular filtration rate is reduced. The fibrinolytic system activity decreases and fibrin is deposited in glomerular capillaries. Hypoxia, which is easy to produce capillary embolism and microcirculation disturbance, reduces kidney function, rhubarb can improve amino acid metabolism, inhibit mesangial cell proliferation, resist damage of kidney growth factor to kidney tissue, inhibit renal tubule metabolism and promote excretion of intestinal ammoniated metabolites; and Chinese herbs for promoting blood circulation and removing blood stasis, such as Chinese angelica, szechuan lovage rhizome, safflower, panax notoginseng, clematis root, wood louse, drynaria rhizome and the like, have the great effects of nourishing blood and promoting blood circulation, reducing platelet aggregation, blood viscosity and K value, expanding blood vessels and increasing renal blood flow. Also has great effects on nourishing liver and kidney, nourishing essence and blood and improving the overall condition.
Chronic nephritis is not a single disease, and the pathology and outcome involve multiple systems, clinical manifestations, pathological changes are also variable, cold and heat, deficiency and excess are complicated. Sometimes it can be accompanied by exogenous pathogenic factors and damp-heat, and when it is added, huang Bai can clear damp-heat in lower energizer.
It is demonstrated that chronic nephritis is near the end of its life, especially in diabetic renal patients, who are already very weak. Renal function is poor. The large amount of oral medication may further impair kidney function. Because both Chinese and Western medicines are generally absorbed by intestinal tract, they are detoxified by liver and mostly excreted by kidney.
Due to the special position of the kidney, it is located on both sides of the spine, clinging to the posterior abdominal wall behind the peritoneum and in close proximity to the body surface. Therefore, partial medicines can be designed to be externally used, so that the medicines can act on the kidney without increasing the burden of the kidney, and most of the medicine for promoting blood circulation and removing blood stasis is designed to be changed into a black plaster.
Currently, the most common transdermal agents used medically are dimethyl sulfoxide and azone. Dimethyl sulfoxide is an inert liquid, can dissolve effective components of various traditional Chinese medicines without destroying the components, and can deliver the medicines to deep tissues of human bodies. The azone has stronger penetrability which is 5 to 10 times stronger than that of dimethyl sulfoxide but is more active than dimethyl sulfoxide, and has no great adverse effect on the treatment effect. Has obvious curative effect.
Drawings
FIG. 1 is an assay report for case 1;
FIG. 2 is an assay report for case 1;
FIG. 3 is an assay report for case 2;
FIG. 4 is the test report for case 2;
FIG. 5 is the test report for case 3;
FIG. 6 is the test report for case 3;
FIG. 7 is the test report of case 4;
FIG. 8 is the test report for case 4;
FIG. 9 is a member of the Consortium of physicians in the global license of the inventor;
Detailed Description
The invention is further described below with reference to the accompanying drawings. The following examples are only for illustrating the technical solutions of the present invention more clearly, and the protection scope of the present invention is not limited thereby.
Example 1: a traditional Chinese medicine composition for treating chronic renal failure comprises uremia detoxification powder for oral administration and a Shenshu black plaster for external use for strengthening spleen, tonifying kidney and improving kidney blood flow, wherein the uremia detoxification powder comprises the following medicinal materials in parts by weight: 15 parts of lychee seed and 5 parts of cordyceps militaris or cordyceps sinensis, wherein the Shenshu black plaster comprises the following Chinese medicinal powder consisting of the following medicinal materials in parts by weight: 720 parts of safflower, 450 parts of pseudo-ginseng, 480 parts of rhubarb, 720 parts of frankincense, 720 parts of myrrh, 600 parts of sappan wood, 600 parts of twig, 450 parts of wood louse, 480 parts of native copper, 300 parts of ligusticum wallichii, 360 parts of angelica, 360 parts of radix clematidis, 480 parts of rhizoma drynariae and 480 parts of golden cypress, wherein the Shenshu black plaster is pasted on the Shenshu acupoint of the waist and the surrounding skin when in use; the uremia toxin-removing powder is decocted with pig waist and rice washing water, and then dregs are removed for oral administration.
The Shenshu black plaster consists of 1000g of hot melt adhesive matrix, 300 to 350g of traditional Chinese medicine powder and 100g of plaster adjuvant powder. Heating 1000g of hot melt adhesive matrix to melt, wherein the melting temperature is within the range of 120-140 ℃, the highest temperature can not exceed 150 ℃, melting while stirring, completely melting to be fluidized, turning to small fire, adding the traditional Chinese medicine powder and the plaster auxiliary material powder, stirring uniformly, covering an isolation membrane in the middle of a plaster cloth, and flattening to obtain the plaster.
The plaster auxiliary material powder consists of one or more of penetrant azone powder, far infrared ceramic powder, analgesic powder, antiallergic powder and heating agent, and the heating agent is capsaicin heating agent or oil vanilla heating agent.
Example 2: a traditional Chinese medicine composition for treating chronic renal failure comprises uremia toxin detoxification powder for oral administration and a Shenshu black plaster for external use for strengthening spleen, tonifying kidney and improving kidney blood flow, wherein the uremia toxin detoxification powder comprises the following medicinal materials in parts by weight: 15 parts of lychee seed, 5 parts of cordyceps militaris or cordyceps sinensis, wherein the Shenshu black paste comprises traditional Chinese medicine powder consisting of the following medicinal materials in parts by weight: 720 parts of safflower, 450 parts of pseudo-ginseng, 480 parts of rhubarb, 720 parts of frankincense, 720 parts of myrrh, 600 parts of sappan wood, 600 parts of cape jasmine, 450 parts of wood louse, 480 parts of native copper, 300 parts of ligusticum wallichii, 360 parts of angelica, 360 parts of radix clematidis, 480 parts of rhizoma drynariae and 480 parts of golden cypress, wherein the Shenshu black plaster is stuck on the Shenshu acupoint at the waist and the surrounding skin when in use; the uremia toxin-removing powder is orally taken after being boiled with pig waist and rice washing water and dregs are removed.
The Shenshu black plaster consists of 1000g of hot melt adhesive matrix, 300 to 350g of Chinese medicinal powder and 100g of plaster adjuvant powder. Heating 1000g of hot melt adhesive matrix to melt, wherein the melting temperature is within the range of 120-140 ℃, the highest temperature can not exceed 150 ℃, melting while stirring, completely melting to be fluidized, turning to small fire, adding the traditional Chinese medicine powder and the plaster auxiliary material powder, stirring uniformly, covering an isolation membrane in the middle of a plaster cloth, and flattening to obtain the plaster.
The plaster auxiliary material powder comprises penetrant azone powder, far infrared ceramic powder, analgesic powder, antiallergic powder and heating agent according to the ratio of 20 to 40:30 to 50:10 to 30 parts by weight, and. The heating agent is capsaicin or oil vanilla.
Example 3:
the inventor is a humble and modest physician in the department of puting, guangdong province, and a member of the global licensed medical society of medical scientists, and the formula cures a plurality of patients, and the following 4 cases are treated by the method.
Case 1
Qin-jiao, male, 48 years old (2015 years old)
12/2015, 9-day laboratory report (see figure 1): urea nitrogen 19.82 and creatinine 834.32.
Treatment with the method of the invention begins on day 11 of 12 months 2015.
12/2015 14-day laboratory report (see figure 2): urea nitrogen 18.45 and creatinine 649.
Creatinine was reduced by about 200 units over 3 days of treatment.
Case 2
Chen in a year of age 46 years old (2015)
Hospital examination at 11/29/2015 (see fig. 3), urea nitrogen 20.77, creatinine 354, and then begin to receive treatment according to the method of the present invention.
Hospital examination of 2016, 1, 8, urea nitrogen 17.14, creatinine 403, and total protein 52.7.
2016 (see FIG. 4): urea nitrogen 16.80, creatinine 442.
Case 3
Qinzhi, male, age 68
Hospital survey 2 month and 5 days in 2020 (see figure 6): urea nitrogen 11.54, creatinine 212, total protein 48.6 (generalized edema).
Hospital admission check in day 3, month 17: urea nitrogen 11.35, creatinine 211.62.
Hospital survey of 5 month and 29 days in 2020: urea nitrogen 15.32, creatinine 234.9, and total protein 54.8.
Treatment with the method of the invention is started thereafter.
Reexamination at 9, 8 days in 2020: urea nitrogen 8.20, creatinine 158, total protein 57.3.
Check 1/4/2021 (see figure 5): urea nitrogen 7.87, creatinine 178, total protein 61.9 (edema disappeared).
The treatment is still carried out until now, the urea nitrogen is kept within 10 points, the creatinine is not over 200, and the normal life and work can be realized.
Case 4
He somehow, male, 71 years old (2020 age)
The history of diabetes is more than 10 years, and in recent years, the treatment of reducing blood sugar by injecting insulin is provided.
In 2020, about half of more than one month before 3, 18 days, the sunken edema below the knee joints of both lower limbs is found, and then the patient looks up urine in a hospital to see 555mg/24h of urine protein, urine sugar + + +, urine protein +, and the stage II of diabetic nephropathy is to be diagnosed. Treatment with the method of the invention was started thereafter and reviewed by 6/2020 (see FIG. 7): urine glucose +, urine protein ±,10mg/24h, the rest is normal; renal function examination, 10.16 blood sugar, urea nitrogen, creatinine and other normal ranges, edema disappeared and basically cured. Continue consolidation therapy to the end of 6 months and stop therapy. The treatment is consolidated for twenty days every three months to half a year, and no special discomfort exists till now.
Finally, it should be noted that: it should be understood that the above examples are only for clearly illustrating the present invention and are not intended to limit the embodiments. Other variations and modifications will be apparent to persons skilled in the art in light of the above description. And are neither required nor exhaustive of all embodiments. And obvious variations or modifications are intended to be within the scope of the present invention.

Claims (8)

1. The traditional Chinese medicine composition for treating chronic renal failure is characterized by comprising an oral uremia toxin-removing powder and an external Shenshu black plaster, wherein the uremia toxin-removing powder comprises the following medicinal materials in parts by weight: 15 parts of lychee seed, 5 parts of cordyceps militaris or cordyceps sinensis, wherein the Shenshu black paste comprises traditional Chinese medicine powder consisting of the following medicinal materials in parts by weight: 720 parts of safflower, 450 parts of pseudo-ginseng, 480 parts of rhubarb, 720 parts of frankincense, 720 parts of myrrh, 600 parts of sappan wood, 600 parts of twig, 450 parts of wood louse, 480 parts of native copper, 300 parts of ligusticum wallichii, 360 parts of angelica, 360 parts of radix clematidis, 480 parts of rhizoma drynariae and 480 parts of golden cypress.
2. The traditional Chinese medicine composition for treating chronic renal failure according to claim 1, wherein the uremia toxin-removing powder is orally taken after decoction together with pig loins and rice water and residue removal.
3. The traditional Chinese medicine composition for treating chronic renal failure as claimed in claim 1, wherein the Shenshu black plaster comprises a hot melt adhesive matrix, traditional Chinese medicine powder and plaster adjuvant powder.
4. The traditional Chinese medicine composition for treating chronic renal failure as claimed in claim 3, wherein the Shenshu black plaster is prepared by mixing the hot melt adhesive matrix, the traditional Chinese medicine powder and plaster adjuvant powder according to the ratio of 1000:300 to 350.
5. The traditional Chinese medicine composition for treating chronic renal failure according to claim 4, wherein the plaster adjuvant powder comprises one or more of penetrant azone powder, far infrared ceramic powder, analgesic powder, antiallergic powder and exothermic agent.
6. The traditional Chinese medicine composition for treating chronic renal failure according to claim 4, wherein the plaster adjuvant powder comprises penetrant azone powder, far infrared ceramic powder, analgesic powder, antiallergic powder and heating agent according to the ratio of 20-40: 30 to 50:10 to 30 parts by weight, and.
7. The traditional Chinese medicine composition for treating chronic renal failure according to claim 6, wherein the exothermic agent is a capsaicin exothermic agent or an oil vanilla exothermic agent.
8. The traditional Chinese medicine composition for treating chronic renal failure according to claim 4, wherein the Shenshu black plaster is prepared by melting 1000g of hot melt adhesive matrix by heating, wherein the melting temperature is within the range of 120-140 ℃, the maximum temperature can not exceed 150 ℃, stirring while melting, turning into a fluidized state after complete melting, using a small fire, adding the traditional Chinese medicine powder and the plaster auxiliary material powder, stirring uniformly, covering the middle of a plaster cloth with an isolating membrane, and pressing flatly.
CN202211086171.1A 2022-09-06 2022-09-06 Traditional Chinese medicine composition for treating chronic renal failure Active CN115400175B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211086171.1A CN115400175B (en) 2022-09-06 2022-09-06 Traditional Chinese medicine composition for treating chronic renal failure

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211086171.1A CN115400175B (en) 2022-09-06 2022-09-06 Traditional Chinese medicine composition for treating chronic renal failure

Publications (2)

Publication Number Publication Date
CN115400175A true CN115400175A (en) 2022-11-29
CN115400175B CN115400175B (en) 2024-01-26

Family

ID=84163017

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211086171.1A Active CN115400175B (en) 2022-09-06 2022-09-06 Traditional Chinese medicine composition for treating chronic renal failure

Country Status (1)

Country Link
CN (1) CN115400175B (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526324A (en) * 2012-01-12 2012-07-04 张福成 Medicine for treating chronic renal failure and preparation method thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102526324A (en) * 2012-01-12 2012-07-04 张福成 Medicine for treating chronic renal failure and preparation method thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
勇志;段利民;张灵芝;: "活血化瘀中药在慢性肾衰竭衰竭期治疗中的疗效观察", 辽宁中医杂志, vol. 42, no. 04, pages 790 *
唐雅文: "慢性肾功能衰竭中药灌肠的临床观察及护理", 护理学杂志, no. 05, pages 298 *
飞龙在天COKVJ5: "民间偏方 尿毒症特性秘验方汇编", pages 1 - 2, Retrieved from the Internet <URL:http://www.360doc.com/content/21/1122/04/47720639_1005322721.shtml> *

Also Published As

Publication number Publication date
CN115400175B (en) 2024-01-26

Similar Documents

Publication Publication Date Title
CN101391077B (en) Preparation method of traditional Chinese medicine for treating chronic pelvic inflammatory disease
CN102872411A (en) Traditional Chinese medicine composition for treating jaundice
CN102319341B (en) Chinese medicinal compound for treating and preventing diabetes
CN101972446B (en) Medicament for treating coronary disease and preparation method thereof
CN102579610B (en) Chinese medicinal composition for treating cerebral hemorrhage and preparation method thereof
CN101987135B (en) Medicine for treating tetanus and preparation method thereof
CN108186749A (en) Treat Chinese medicine composition of cervical spondylosis and preparation method thereof
CN108261505A (en) A kind of drug of logical stalkization bolt and preparation method thereof
CN101032619A (en) Liquid medicine to be taken orally for curing primary hypertension and the preparing method
CN115400175A (en) Traditional Chinese medicine composition for treating chronic renal failure
CN106344772A (en) traditional Chinese medicine composition for treating rhinitis, external preparation and preparation method thereof
CN105169078A (en) Traditional Chinese medicinal composition for treating diabetes
CN107260978B (en) Traditional Chinese medicine composition for treating hypertension and preparation method and application thereof
CN105106634A (en) Traditional Chinese medicine preparation for treating acute appendicitis and application thereof
CN104998158A (en) Pharmaceutical composition for treating liver cirrhosis and application thereof
CN115957274B (en) Traditional Chinese medicine composition for treating diabetes, blood circulation activating and vein relaxing gel composition and preparation method
CN106581272A (en) Traditional Chinese medicine composition for treating diabetes
CN101890069A (en) Medicament for preventing and treating gout and preparation process thereof
CN108853380B (en) Pharmaceutical composition for treating diabetes and preparation method and application thereof
CN101406569B (en) Chinese medicinal composition for treating cerebrovascular disease, and preparation thereof
CN105213975A (en) A kind of pharmaceutical composition and application thereof for the treatment of liver cirrhosis
CN106110127A (en) A kind of for phthisical Chinese medicine composition
CN106266427A (en) A kind of Traditional Chinese medicinal liquor treating nephropathy and preparation method thereof
CN105477246A (en) Traditional Chinese medicine composition for treating phlegmatic hygrosis type mammary gland hyperplasia and preparation method thereof
CN104873854A (en) Traditional Chinese medicine preparation for rteriolar nephrosclerosis and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant